US20110224213A1 - Use of Glutaric Acid Derivatives or the Pharmaceutically Acceptable Salts Thereof as Anti-Arrhythmic Agents - Google Patents

Use of Glutaric Acid Derivatives or the Pharmaceutically Acceptable Salts Thereof as Anti-Arrhythmic Agents Download PDF

Info

Publication number
US20110224213A1
US20110224213A1 US12/922,958 US92295809A US2011224213A1 US 20110224213 A1 US20110224213 A1 US 20110224213A1 US 92295809 A US92295809 A US 92295809A US 2011224213 A1 US2011224213 A1 US 2011224213A1
Authority
US
United States
Prior art keywords
compound
pharmaceutically acceptable
general formula
compounds
arrhythmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/922,958
Inventor
Vladimir Evgenievich Nebolsin
Dmitry Sergeevich Blinov
Vladimir Pavlovich Balashov
Tatyana Alexandrovna Kromova
Galina Alexandrovna Zheltukhina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "PHARMENTERPRISES"
Original Assignee
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "PHARMENTERPRISES"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "PHARMENTERPRISES" filed Critical OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "PHARMENTERPRISES"
Assigned to OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "PHARMENTERPRISES" reassignment OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "PHARMENTERPRISES" ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BALASHOV, VLADIMIR PAVLOVICH, BLINOV, DMITRY SERGEEVICH, KROMOVA, TATYANA ALEXANDROVNA, NEBOLSIN, VLADIMIR EVGENIEVICH, ZHELTUKHINA, GALINA ALEXANDROVNA
Publication of US20110224213A1 publication Critical patent/US20110224213A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Definitions

  • the instant invention relates to medicine and to the use of glutaric acid derivatives, in particular N-acyl amino acid derivatives and pharmaceutically acceptable salts thereof as anti-arrhythmic agents for correction of disorders in the rhythm of cardiac activity.
  • propranolol anaprilin, obzidan
  • amiodaron cordaron
  • a defect of the known compound is the low anti-arrhythmic activity upon parenteral administration, and also insufficient diapason of therapeutic action.
  • N-acyl derivatives of biogenic amines for example, glutaryl histamine
  • Histidine and tryptophane N-acyl derivatives of amino acids are disclosed in the publication of international application WO 2006/135280, wherein the use thereof as anti-allergic and lipid-controlling agents is described.
  • N-acyl derivatives of amino acids which derivatives have anti-allergic, anti-inflammatory and hypolipidemic action and may be used for the treatment of allergic diseases: bronchial asthma, allergic rhinitis, pollinosis, seasonal rhinitis, year-round rhinitis, atopic dermatitis, psoriasis, hives, allergic (including anaphylactic) reactions to insect bites and drugs, cold allergy, allergic conjunctivitis, chronic obstructive pulmonary diseases, in particular chronic obstructive bronchitis, emphysema, obliterating bronchitis, mucoviscidosis, and also diseases related to disorders of lipid exchange, such as atherosclerosis, obesity, cardial and cerebral ischemia, cardiac infarction, stroke.
  • the object of the instant invention is to use glutaric acid derivatives and the pharmaceutically acceptable salts thereof as anti-arrhythmic agents.
  • the instant invention relates to the use of glutaric acid derivatives of general formula (I):
  • R 2 COOH, —COOCH 3 , —COOC 2 H 5 , H,
  • the instant invention relates to a pharmaceutical composition and to an agent having anti-arrhythmic action, comprising an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and also, if necessary, a pharmaceutically acceptable carrier.
  • One more subject matter of the invention is a method of treating arrhythmia, comprising administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the compounds of general formula (I) may be prepared, for example, as described in RU 2005118635 by adding an anhydride of glutaric or succinic acid in a water-immiscible organic solvent to an aqueous solution of amino acid of the general formula:
  • R 1 is:
  • This method makes it possible to use an excess of an acylating agent, achieve complete acylation of the ⁇ -amino group of amino acid and a yield of the desired product of about 70%.
  • an organic compound—pyridine is used, which does not hydrolyze the anhydride, and, furthermore, as is known, is an acylation catalyst.
  • pyridine makes it possible to avoid impurity of the final product with inorganic salts, which together with the reaction product remain in the aqueous layer.
  • the ways that are used make it possible to simplify separation of the desired product from the unreacted anhydride and corresponding amino acid and isolate the desired product by simple crystallization.
  • the compounds of general formula (I) may also be obtained in the form of pharmaceutically acceptable salts by reaction with, for example, sodium hydroxide, potassium hydroxide, magnesium carbonate, lithium hydroxide, calcium carbonate using routine methods widely described in literature.
  • the compounds of general formula (I) have anti-arrhythmic activity and may be used for treatment of arrhythmia.
  • the compounds of general formula (I) are administered in an effective amount, which provides for the desired therapeutic result.
  • compounds of general formula I may be administered orally and intravenously in the form of standard dosage forms comprising nontoxic pharmaceutically acceptable carriers.
  • Compounds of general formula (I) may be administered to a patient in doses that are from 0.01 to 10 mg per kg of body weight daily, preferably in doses from 0.05 to 5 mg/kg once or more times daily.
  • a concrete dose for each concrete patient will depend on many factors, including the activity of the particularly used compound, age, body weight, sex, general health condition and dietary pattern of the patient, the time and method for administration of the medicament, the rate of its removal from the organism, the combination of specifically used medicaments, and also the severity of the disease of this individual undergoing treatment.
  • compositions according to the instant invention comprise a compound of general formula (I) in an amount that is effective for achievement of the desired result, and may be administered in the form of standard dosage forms (for example, in solid, semisolid or liquid forms), comprising compounds of the instant invention as the active ingredient in a mixture with a carrier or excipient that is suitable for parenteral and oral administration.
  • the active ingredient may be introduced into the composition together with usually used nontoxic pharmaceutically acceptable carriers that are suitable for the preparation of solutions, tablets, pills, capsules, dragée
  • saccharides for example, glucose, lactose or saccharose, mannitol or sorbitol, cellulose derivatives and/or calcium phosphates, for example, tribasic calcium phosphate or calcium acid phosphate
  • Such substances as starch paste, for example, corn, wheat, rice, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxy methylcellulose and/or polyvinylpyrrolidone may be used as the binder component.
  • loosening agents such as the aforesaid starches and carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar or alginic acid or a salt thereof, such as sodium alginate, may be used.
  • agents regulating fluidity such as silicon dioxide, talc, stearic acid and salts thereof, such as magnesium stearate or calcium stearate and/or propylene glycol, may be used.
  • agents regulating fluidity such as silicon dioxide, talc, stearic acid and salts thereof, such as magnesium stearate or calcium stearate and/or propylene glycol.
  • Stabilizers may also be used as additives.
  • the amount of the active ingredient that is used in combination with the carrier may vary depending on the recipient subjected to treatment and also on the concrete method of administering the medicament.
  • the content of the active agent therein is 0.01-5%.
  • a 0.9% solution of sodium chloride, distilled water, a novocaine solution for injection, a Ringer solution, a glucose solution, and specific additives for dissolution may be used as diluents.
  • the content thereof is 5.0-500 mg per standard dosage form.
  • the dosage forms of the instant invention are obtained in accordance with standard methods such as, for example, the processes of mixing, granulating, forming dragees, dissolution and lyophilization.
  • Adrenal disorders of cardiac rhythm were reproduced on pedigreeless white laboratory mice of either sex having a weight of 18-22 g.
  • Experimental arrhythmia in the animals was caused in accordance with the method described in the source Moore E. N., Spear J. F. Acute animal models for the study of antiarrhythmic drugs for the prevention of sudden coronary death.// Clin. Pharmacol. Antiarhythmic Therapy. New-York. 1984. pp. 31-46.
  • the compounds of general formula (I) exceed that of N-succinyl-D,L-tryptophane dipotassium salt, also administered internally.
  • N-succinyl-D,L-tryptophane dipotassium salt the compounds of general formula (I) reliably increase the life span and reduce the frequency of lethal consequences upon administration internally in the studied doses.
  • Arrhythmia was reproduced according to the method of Ju. I. Vikhlyayev and N. V. Kaverina (1958) [Kaverina N. V., Berdyaev S. Ju., Kuschuk E. P., Paskhina O. E. Methodical indications in respect to a study of the anti-arrhythmic activity of new pharmacological substances. Manual on experimental (pre-clinical) study of new pharmacological substances. Edited by V. P. Fisenko.—Moscow. 2000. Page 210]. Aconitine nitrate was administered to the animals in a dose of 50 ⁇ g/kg intravenously.
  • tryptophane potassium salt Compound III per/os 0.185 ⁇ 0.083 4500 24324 Note: *ED 50 was not determined, since in the interval of doses 0.05-5 mg/kg arrhythmia develops in 71-100% of the test animals, while at a dose of 50 mg/kg 50% of the animals died after administration of the substance.
  • the compounds were administered intravenously in doses: compound III (N ⁇ -glutaryl-L-histidine) and N-succinyl-D,L-tryptophane dipotassium salt—0.05 and 0.5 mg/kg, cordaron and propranolol—1.0 mg/kg.
  • N-succinyl-D,L-tryptophan dipotassium salt did not demonstrate a reliable anti-arrhythmic effect upon administration in a dose of 0.05 mg/kg, while the compound III (N ⁇ -glutaryl-L-histidine) upon intravenous administration in the indicated dose had reliable activity.
  • the compound III (N ⁇ -glutaryl-L-histidine) and N-succinyl-D,L-tryptophane dipotassium salt showed similar therapeutic activity.
  • the presented data show that under conditions of modeling acute occlusive damage to the myocardium in cats, the compound III (N ⁇ -glutaryl-L-histidine) upon prophylactic intravenous administration is more effective in a broader range of doses than N-succinyl-D,L-tryptophane dipotassium salt.
  • the compound III (N ⁇ -glutaryl-L-histidine) and N-succinyl-D,L-tryptophane dipotassium salt prevented experimental lethality of the animals in this model, wherein it was 23% in the control.
  • the components are mixed and pressed to form tablets weighing 300 mg each.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the use of glutaric acid derivatives of general formula (I), which are disclosed in the invention description, as anti-arrhythmic agents.

Description

  • The instant invention relates to medicine and to the use of glutaric acid derivatives, in particular N-acyl amino acid derivatives and pharmaceutically acceptable salts thereof as anti-arrhythmic agents for correction of disorders in the rhythm of cardiac activity.
    • BACKGROUND ART
  • It is well-known that at the present time propranolol (anaprilin, obzidan) and amiodaron (cordaron) are anti-arrhythmic agents that are widely used in clinical practice.
  • Their main defects are insufficient effectiveness and low therapeutic diapason, which is manifested by the high frequency of cardial and extracardial side effects. [Mashkovsky M. D. Medicaments. Manual for doctors. Publication 15. Publishing House Novaya Volna. 2005. pages 390-392, 264-266].
  • The analog of the claimed compounds that is closest in respect to action is the N-succinyl-D,L-tryptophane dipotassium salt exhibiting anti-ischemic, cardiotonic and anti-arrhythmic action upon research [Bulletin of experimental biology and medicine. 1998. vol. 125. No. 5. pages 544-547].
  • A defect of the known compound is the low anti-arrhythmic activity upon parenteral administration, and also insufficient diapason of therapeutic action.
  • In view of the aforesaid, what is real is the search for new anti-arrhythmic agents that are capable of manifesting high anti-arrhythmic activity upon parenteral administration and are highly effective upon treatment of disorders of cardiac rhythm.
  • The anti-allergic and hypolipidemic action of N-acyl derivatives of biogenic amines, for example, glutaryl histamine, is described in the publication of international application WO 99/01103.
  • Histidine and tryptophane N-acyl derivatives of amino acids are disclosed in the publication of international application WO 2006/135280, wherein the use thereof as anti-allergic and lipid-controlling agents is described.
  • A description is provided in the publication of application RU 2005118635 of N-acyl derivatives of amino acids, which derivatives have anti-allergic, anti-inflammatory and hypolipidemic action and may be used for the treatment of allergic diseases: bronchial asthma, allergic rhinitis, pollinosis, seasonal rhinitis, year-round rhinitis, atopic dermatitis, psoriasis, hives, allergic (including anaphylactic) reactions to insect bites and drugs, cold allergy, allergic conjunctivitis, chronic obstructive pulmonary diseases, in particular chronic obstructive bronchitis, emphysema, obliterating bronchitis, mucoviscidosis, and also diseases related to disorders of lipid exchange, such as atherosclerosis, obesity, cardial and cerebral ischemia, cardiac infarction, stroke.
  • It was found by the authors of the instant invention that some of the amino acid N-acyl derivatives have anti-arrhythmic action and may be effectively used in the therapy of cardiac rhythm disorders.
  • The object of the instant invention is to use glutaric acid derivatives and the pharmaceutically acceptable salts thereof as anti-arrhythmic agents.
    • BRIEF DESCRIPTION OF THE INVENTION
  • The instant invention relates to the use of glutaric acid derivatives of general formula (I):
  • Figure US20110224213A1-20110915-C00001
  • wherein
  • Figure US20110224213A1-20110915-C00002
  • R2=COOH, —COOCH3, —COOC2H5, H,
  • or pharmaceutically acceptable salts thereof as anti-arrhythmic agents.
  • Further, the instant invention relates to a pharmaceutical composition and to an agent having anti-arrhythmic action, comprising an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and also, if necessary, a pharmaceutically acceptable carrier.
  • One more subject matter of the invention is a method of treating arrhythmia, comprising administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The compounds of general formula (I) are presented in Table I.
  • TABLE I
    No.
    Compound compound R1 R2
    Figure US20110224213A1-20110915-C00003
         		II
    Figure US20110224213A1-20110915-C00004
         		—COOH
    Figure US20110224213A1-20110915-C00005
         		III
    Figure US20110224213A1-20110915-C00006
         		—COOH
    Figure US20110224213A1-20110915-C00007
         		IV
    Figure US20110224213A1-20110915-C00008
         		H
    Figure US20110224213A1-20110915-C00009
         		V
    Figure US20110224213A1-20110915-C00010
         		—COOC2H5
    Figure US20110224213A1-20110915-C00011
         		VI
    Figure US20110224213A1-20110915-C00012
         		—COOC2H5
    Figure US20110224213A1-20110915-C00013
         		VII
    Figure US20110224213A1-20110915-C00014
         		—COOCH3
    Figure US20110224213A1-20110915-C00015
         		VIII
    Figure US20110224213A1-20110915-C00016
         		—COOCH3
    Figure US20110224213A1-20110915-C00017
         		IX
    Figure US20110224213A1-20110915-C00018
         		H
    Figure US20110224213A1-20110915-C00019
         		X
    Figure US20110224213A1-20110915-C00020
         		H
    Figure US20110224213A1-20110915-C00021
         		XI
    Figure US20110224213A1-20110915-C00022
         		H
    Figure US20110224213A1-20110915-C00023
         		XII
    Figure US20110224213A1-20110915-C00024
         		H
    Figure US20110224213A1-20110915-C00025
         		XIII
    Figure US20110224213A1-20110915-C00026
         		H
    Figure US20110224213A1-20110915-C00027
         		XIV
    Figure US20110224213A1-20110915-C00028
         		H
    Figure US20110224213A1-20110915-C00029
         		XV
    Figure US20110224213A1-20110915-C00030
         		H
    Figure US20110224213A1-20110915-C00031
         		XVI
    Figure US20110224213A1-20110915-C00032
         		H
    Figure US20110224213A1-20110915-C00033
         		XVII
    Figure US20110224213A1-20110915-C00034
         		H
    Figure US20110224213A1-20110915-C00035
         		XVIII
    Figure US20110224213A1-20110915-C00036
         		H
    Figure US20110224213A1-20110915-C00037
         		XI
    Figure US20110224213A1-20110915-C00038
         		H
    Figure US20110224213A1-20110915-C00039
         		XX
    Figure US20110224213A1-20110915-C00040
         		H
    Figure US20110224213A1-20110915-C00041
         		XXI
    Figure US20110224213A1-20110915-C00042
         		H
    Figure US20110224213A1-20110915-C00043
         		XXII
    Figure US20110224213A1-20110915-C00044
         		H
  • The compounds of general formula (I) may be prepared, for example, as described in RU 2005118635 by adding an anhydride of glutaric or succinic acid in a water-immiscible organic solvent to an aqueous solution of amino acid of the general formula:
  • Figure US20110224213A1-20110915-C00045
  • wherein R1 is:
  • Figure US20110224213A1-20110915-C00046
  • This method makes it possible to use an excess of an acylating agent, achieve complete acylation of the α-amino group of amino acid and a yield of the desired product of about 70%. In order to support the necessary pH an organic compound—pyridine, is used, which does not hydrolyze the anhydride, and, furthermore, as is known, is an acylation catalyst. The use of pyridine makes it possible to avoid impurity of the final product with inorganic salts, which together with the reaction product remain in the aqueous layer. The ways that are used make it possible to simplify separation of the desired product from the unreacted anhydride and corresponding amino acid and isolate the desired product by simple crystallization.
  • The compounds of general formula (I) may also be obtained in the form of pharmaceutically acceptable salts by reaction with, for example, sodium hydroxide, potassium hydroxide, magnesium carbonate, lithium hydroxide, calcium carbonate using routine methods widely described in literature.
  • The compounds of general formula (I) have anti-arrhythmic activity and may be used for treatment of arrhythmia.
  • The compounds of general formula (I) are administered in an effective amount, which provides for the desired therapeutic result.
  • In order to provide treatment of arrhythmia, compounds of general formula I may be administered orally and intravenously in the form of standard dosage forms comprising nontoxic pharmaceutically acceptable carriers.
  • Compounds of general formula (I) may be administered to a patient in doses that are from 0.01 to 10 mg per kg of body weight daily, preferably in doses from 0.05 to 5 mg/kg once or more times daily.
  • Wherein, it should be noted that a concrete dose for each concrete patient will depend on many factors, including the activity of the particularly used compound, age, body weight, sex, general health condition and dietary pattern of the patient, the time and method for administration of the medicament, the rate of its removal from the organism, the combination of specifically used medicaments, and also the severity of the disease of this individual undergoing treatment.
  • The pharmaceutical compositions according to the instant invention comprise a compound of general formula (I) in an amount that is effective for achievement of the desired result, and may be administered in the form of standard dosage forms (for example, in solid, semisolid or liquid forms), comprising compounds of the instant invention as the active ingredient in a mixture with a carrier or excipient that is suitable for parenteral and oral administration. The active ingredient may be introduced into the composition together with usually used nontoxic pharmaceutically acceptable carriers that are suitable for the preparation of solutions, tablets, pills, capsules, dragée
  • and any other dosage forms.
  • Different substances, such as saccharides, for example, glucose, lactose or saccharose, mannitol or sorbitol, cellulose derivatives and/or calcium phosphates, for example, tribasic calcium phosphate or calcium acid phosphate may be used as the filler. Such substances as starch paste, for example, corn, wheat, rice, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxy methylcellulose and/or polyvinylpyrrolidone may be used as the binder component. If necessary, loosening agents, such as the aforesaid starches and carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar or alginic acid or a salt thereof, such as sodium alginate, may be used.
  • Optional additives, for example, agents regulating fluidity, and lubricating agents, such as silicon dioxide, talc, stearic acid and salts thereof, such as magnesium stearate or calcium stearate and/or propylene glycol, may be used.
  • Stabilizers, thickeners, dyes and aromatizers may also be used as additives.
  • Upon the preparation of a standard dosage form, the amount of the active ingredient that is used in combination with the carrier may vary depending on the recipient subjected to treatment and also on the concrete method of administering the medicament.
  • So, for example, upon the use of compounds of general formula (I) in the form of solutions for injection, the content of the active agent therein is 0.01-5%. A 0.9% solution of sodium chloride, distilled water, a novocaine solution for injection, a Ringer solution, a glucose solution, and specific additives for dissolution may be used as diluents. Upon the administration into the organism of compounds of the instant invention in the form of tablets, the content thereof is 5.0-500 mg per standard dosage form.
  • The dosage forms of the instant invention are obtained in accordance with standard methods such as, for example, the processes of mixing, granulating, forming dragees, dissolution and lyophilization.
  • A study in detail of the pharmacological activity of compounds of general formula (I) is presented in the following examples.
    • Results of a Study of the Pharmacological Activity of Compounds of General Formula (I) Example 1 Anti-Arrhythmic Activity of Compounds of General Formula (I) and N-succinyl-D,L-tryptophane Dipotasassium Salt and Also the Effect Thereof on Mortality Upon Adrenal Arrhythmia in Mice
  • Adrenal disorders of cardiac rhythm were reproduced on pedigreeless white laboratory mice of either sex having a weight of 18-22 g. Experimental arrhythmia in the animals was caused in accordance with the method described in the source Moore E. N., Spear J. F. Acute animal models for the study of antiarrhythmic drugs for the prevention of sudden coronary death.// Clin. Pharmacol. Antiarhythmic Therapy. New-York. 1984. pp. 31-46.
  • The results of comparative testing of the claimed compounds and N-succinyl-D,L-tryptophane dipotasassium salt are presented in Table 2.
  • TABLE 2
    Effectiveness of compounds of general formula (I) and N-succinyl-D,L-
    tryptophane dipotasassium salt upon adrenal intoxication in mice
    Number of animals in groups
    with
    Trial conditions, dose ventricular with AV Lifetime
    No. (mg/kg) in trial arrhythmia blockage lethal (min)
    1 Control 14 14 (100%) 14 (100%) 14 (100%) 15 ± 2 
    2 Propranolol (0.1) 14 4* (29%) 5* (36%) 12 (86%) 20 ± 4 
    Propranolol (0.5) 14 7* (50%) 4* (29%) 11 (79%) 23 ± 4*
    3 N-succinyl-D,L- 14 6* (43%) 6* (43%) 14 (100%) 16 ± 4 
    tryptophane
    dipotassium salt (0.05)
    4 N-succinyl-D,L- 14 6* (43%) 8 (57%) 14 (100%) 16 ± 4 
    tryptophane
    dipotassium salt (0.5)
    5 Compound III (0.05) 14 6* (43%) 4* (29%) 12 (86%) 32 ± 7*
    6 Compound III (0.5) 14 4* (29%) 3* (21%) 11 (79%) 33 ± 5*
    7 Compound II 14 0* (0%) 5* (36%) 7* (50%)  19 ± 2.8
    mono-sodium salt
    0.5 mg/kg
    8 Compound II 14 0* (0%) 0* (0%) 7* (50%)  22 ± 3.4
    mono-sodium salt
    0.05 mg/kg
    9 Compound IV 14 2* (14%) 4* (29%) 14 (100%)  18 ± 0.8
    0.5 mg/kg
    10 Compound IV 14 4* (29%) 3* (21%) 11 (79%) 24 ± 3*
    0.05 mg/kg
    11 Compound II 14 0* (0%) 4* (29%) 7* (50%)  19 ± 2.8
    0.5 mg/kg
    12 Compound II 14 0* (0%) 0* (0%) 7* (50%)  22 ± 3.4
    0.05 mg/kg
    13 Compound XIII 14 3* (21%) 4* (29%) 5* (36%) 28 ± 9*
    mono-sodium salt
    0.5 mg/kg
    14 Compound XIII 14 5* (36%) 6* (43%) 6* (43%) 17 ± 4 
    mono-sodium salt
    0.05 mg/kg
    15 Compound X 10 3* (30%) 6 (60%) 7* (70%) 27 ± 6*
    0.5 mg/kg
    16 Compound X 10 6* (60%) 7 (70%) 7* (70%) 13 ± 4 
    0.05 mg/kg
    17 Compound IX, 10 2* (20%) 5 (50%) 6* (60%) 32 ± 4*
    0.5 mg/kg
    18 Compound IX 10 7 (70%) 10 (100%) 8 (80%) 21 ± 6 
    0.05 mg/kg
    *P < 0.05 versus the control group
    AV—atrioventricular.
  • Results of Testing
  • Compounds of general formula (I), introduced internally in doses of 0.05 and 0.5 mg/kg, had an expressed anti-arrhythmic effect: they prevented the development of blockades for carrying out and episodes of ventricular tachycardia. Wherein, the substances had a number of specificities in the effect on the death [mortality] rate of the test animals. The compound Nα-glutaryl-L-histidine (0.05 and 0.5 mg/kg), and also glutaryl histamine (in a dose of 0.05 mg/kg) effectively increased the life span of the test animals, while the compound mono-sodium salt Nα-glutaryl-L-tryptophane (0.05 and 0.5 mg/kg) statistically reliably reduced the lethality of the test animals. The low lethality upon the administration of a compound of the mono-sodium salt of Nα-glutaryl-L-tryptophane combined with elimination of the ventricular ectopic complexes in all of the test animals.
  • So, in respect to the degree of anti-arrhythmic action the compounds of general formula (I) exceed that of N-succinyl-D,L-tryptophane dipotassium salt, also administered internally. In contrast to N-succinyl-D,L-tryptophane dipotassium salt, the compounds of general formula (I) reliably increase the life span and reduce the frequency of lethal consequences upon administration internally in the studied doses.
    • Example 2 Activity of Compound III (Nα-glutaryl-L-histidine) and of N-succinyl-D,L-tryptophane Dipotassium Salt on Models of Aconitic Arrhythmia in Mice
  • Arrhythmia was reproduced according to the method of Ju. I. Vikhlyayev and N. V. Kaverina (1958) [Kaverina N. V., Berdyaev S. Ju., Kuschuk E. P., Paskhina O. E. Methodical indications in respect to a study of the anti-arrhythmic activity of new pharmacological substances. Manual on experimental (pre-clinical) study of new pharmacological substances. Edited by V. P. Fisenko.—Moscow. 2000. Page 210]. Aconitine nitrate was administered to the animals in a dose of 50 μg/kg intravenously.
  • This model makes it possible to assess the scope of the therapeutic action of the presented compounds and the N-succinyl-D,L-tryptophane dipotassium salt. Assessment of the scope of the therapeutic action was carried out in accordance with the value of the anti-arrhythmic index (AAI), determined as the ratio LD50 upon the oral method of administering to ED50 on an aconitic model of arrhythmia. The results of the calculations are presented in Table 3.
  • TABLE 3
    Effective doses, LD50, AAI for the compound III (Nα-glutaryl-L-histidine)
    and N-succinyl-D,L-tryptophane dipotassium salt, calculated in
    respect to an aconitic model of arrhythmia in mice
    Method of LD50, mg/kg AAI
    Tested adminis- ED50, (per/os (LD50/
    preparation tration mg/kg mice) ED50)
    N-succinyl-D,L- per/os Het* N.d.
    tryptophane
    potassium salt
    Compound III per/os 0.185 ± 0.083 4500 24324
    Note:
    *ED50 was not determined, since in the interval of doses 0.05-5 mg/kg arrhythmia develops in 71-100% of the test animals, while at a dose of 50 mg/kg 50% of the animals died after administration of the substance.
  • The experiment that was carried out shows that compound III (Nα-glutaryl-L-histidine) upon administration internally effectively prevents atrioventricular heart arrhythmia caused by the intravenous administration of aconitine nitrate. Wherein the meaning of ED50, calculated for the compound III (Nα-glutaryl-L-histidine), shows that the compound III (Nα-glutaryl-L-histidine) has a broader scope of therapeutic action than N-succinyl-D,L-tryptophane dipotassium salt, which shows that the former (compound III) is safer upon equivalent activity.
    • Example 3 A Study of the Effect of Compound III (Nα-glutaryl-L-histidine) and of N-succinyl-D,L-tryptophane Dipotassium Salt on the Course of Early Occlusive Arrhythmia in Cats
  • At present, in order to assess the effectiveness of therapy under conditions of transistor ischemic arrhythmogenesis, a method is used that is described by Storozhuk V G. [Antifibrilic activity of some anti-arrhythmic agents upon maximum coronary artery ligation and the reperfusion thereof in cats. Pharmacology and Toxicology. 1985. No. 3, pp. 47-49].
  • The results of a study of compound III (Nα-glutaryl-L-histidine), N-succinyl-D,L-tryptophane dipotassium salt and classical anti-arrhythmics are presented in Table 4.
  • TABLE 4
    Anti-arrhythmic activity of compound III (Nα-glutaryl-L-histidine),
    comparative preparations and N-succinyl-D,L-tryptophane dipotassium
    salt on models of occlusive arrhythmia in cats
    Studied Number of Time of
    substance or animals with occurrence of Animals
    preparation, ventricular arrhythmia, died in
    No. dose (mg/kg) n arrhythmia min group
    1 Control 31 23 (74%)  18 ± 5 7 (23%)
    2 Propranolol (1.0) 7 2 (28%)* 24 ± 1 0
    3 Cordaron (1.0) 10 4 (40%)* 21 ± 6 0
    6 N-succinyl-D,L- 6 3 (50%)  19 ± 3 0
    tryptophane
    dipotassium salt
    (0.05)
    7 N-succinyl-D,L- 6 1 (17%)* 21 0
    tryptophane
    dipotassium salt
    (0.5)
    8 Compound III 8 2 (25%)* 18 ± 2 0
    (0.05)
    9 Compound III (0.5) 6 1 (17%)* 18 0
    10 Compound II (0.05) 7 6 (86%)  17 ± 2 1 (14%)
    11 Compound II (0.5) 7 2 (29%)* 17-20 0
    Note:
    *distinctions from corresponding index in control reliable at p < 0.05.
  • The compounds were administered intravenously in doses: compound III (Nα-glutaryl-L-histidine) and N-succinyl-D,L-tryptophane dipotassium salt—0.05 and 0.5 mg/kg, cordaron and propranolol—1.0 mg/kg.
  • In the control, ligation of the coronary artery in cats was accompanied by development of ventricular arrhythmia in 74% of the tests. N-succinyl-D,L-tryptophan dipotassium salt did not demonstrate a reliable anti-arrhythmic effect upon administration in a dose of 0.05 mg/kg, while the compound III (Nα-glutaryl-L-histidine) upon intravenous administration in the indicated dose had reliable activity. In a dose of 0.5 mg/kg, the compound III (Nα-glutaryl-L-histidine) and N-succinyl-D,L-tryptophane dipotassium salt showed similar therapeutic activity.
  • The presented data show that under conditions of modeling acute occlusive damage to the myocardium in cats, the compound III (Nα-glutaryl-L-histidine) upon prophylactic intravenous administration is more effective in a broader range of doses than N-succinyl-D,L-tryptophane dipotassium salt.
  • The compound III (Nα-glutaryl-L-histidine) and N-succinyl-D,L-tryptophane dipotassium salt prevented experimental lethality of the animals in this model, wherein it was 23% in the control.
  • So, the study of compounds of general formula (I) on different models upon peroral and intravenous administration makes it possible to increase the effectiveness and safety of carrying out anti-arrhythmic therapy. The advantage of the claimed compounds is the large scope of therapeutic action.
  • Examples of Dosage Forms
  • A. Tableted Form
  • A tableted form is obtained, using the ingredients indicated below:
  •
    Compound corresponding to general formula (I) 1-150 mg
    or a pharmaceutically acceptable salt thereof
    Potato starch 20-50 mg
    Magnesium stearate 3 mg
    Aerosyl 1 mg
    Lactose to 300 mg
  • The components are mixed and pressed to form tablets weighing 300 mg each.
  • B. Solution for Injections
  • Example of the makeup of a solution for injection:
  •
    Compound corresponding to general formula (I) 0.2-20 mg
    or a pharmaceutically acceptable salt thereof
    Water for injection 2 ml

Claims (5)

1. Use of compounds of general formula (I):
Figure US20110224213A1-20110915-C00047
wherein
Figure US20110224213A1-20110915-C00048
R2=COOH, —COOCH3, —COOC2H5, H,
or a pharmaceutically acceptable salt thereof as an anti-arrhythmic agent.
2. Use of compounds of general formula (I):
Figure US20110224213A1-20110915-C00049
wherein
Figure US20110224213A1-20110915-C00050
R2=COOH, —COOCH3, —COOC2H5, H,
or a pharmaceutically acceptable salt thereof for the production of a medicament having anti-arrhythmic activity.
3. A pharmaceutical composition having anti-arrhythmic activity, comprising a compound of general formula (I):
Figure US20110224213A1-20110915-C00051
wherein
Figure US20110224213A1-20110915-C00052
R2=COOH, —COOCH3, —COOC2H5, H,
or a pharmaceutically acceptable salt thereof in an effective amount and a pharmaceutically acceptable carrier.
4. A medicament having anti-arrhythmic activity, comprising a compound of general formula (I):
Figure US20110224213A1-20110915-C00053
wherein
Figure US20110224213A1-20110915-C00054
R2=COOH, —COOCH3, —COOC2H5, H,
or a pharmaceutically acceptable salt thereof.
5. A method of treating arrhythmia comprising administering to a mammal an effective amount of a compound of general formula (I):
Figure US20110224213A1-20110915-C00055
wherein
Figure US20110224213A1-20110915-C00056
R2=COOH, —COOCH3, —COOC2H5, H,
or a pharmaceutically acceptable salt thereof.
US12/922,958 2008-03-19 2009-03-18 Use of Glutaric Acid Derivatives or the Pharmaceutically Acceptable Salts Thereof as Anti-Arrhythmic Agents Abandoned US20110224213A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2008110644/15A RU2373934C1 (en) 2008-03-19 2008-03-19 Application of glutaric acid derivatives or their pharmaceutically acceptable salts as antiarrhythmic drug
RU2008110644 2008-03-19
PCT/RU2009/000133 WO2009116896A1 (en) 2008-03-19 2009-03-18 Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2009/000133 A-371-Of-International WO2009116896A1 (en) 2008-03-19 2009-03-18 Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/961,019 Division US8912185B2 (en) 2008-03-19 2013-08-07 Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents

Publications (1)

Publication Number Publication Date
US20110224213A1 true US20110224213A1 (en) 2011-09-15

Family

ID=41091132

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/922,958 Abandoned US20110224213A1 (en) 2008-03-19 2009-03-18 Use of Glutaric Acid Derivatives or the Pharmaceutically Acceptable Salts Thereof as Anti-Arrhythmic Agents
US13/961,019 Expired - Fee Related US8912185B2 (en) 2008-03-19 2013-08-07 Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/961,019 Expired - Fee Related US8912185B2 (en) 2008-03-19 2013-08-07 Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents

Country Status (5)

Country Link
US (2) US20110224213A1 (en)
EA (1) EA018127B1 (en)
RU (1) RU2373934C1 (en)
UA (1) UA104420C2 (en)
WO (1) WO2009116896A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382179A (en) * 2013-06-05 2013-11-06 四川百利药业有限责任公司 Ingavirin polymorph and its preparation method
CN105307650A (en) * 2014-01-20 2016-02-03 瓦伦塔有限责任公司 Tablet-formed pharmaceutical composition and preparation method thereof
CN105435233A (en) * 2014-08-06 2016-03-30 江苏正大丰海制药有限公司 Ingavrin pharmaceutical composition
KR20160128416A (en) * 2014-03-12 2016-11-07 오브셰스트보 에스 오그라니첸노이 오트베트스트벤노스티주 “파름엔터프라지즈” Amide compounds and methods for the production and use thereof
US20170023593A1 (en) * 2014-04-03 2017-01-26 Koninklijke Philips N.V. High sensitive detection of melatonin
RU2665638C1 (en) * 2017-05-24 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Amide compound , and use as agents for treatment and prevention of diseases caused by rna-containing viruses
CN113861096A (en) * 2021-10-19 2021-12-31 中国农业大学 Compound containing indole structure, preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050180953A1 (en) * 2002-02-28 2005-08-18 Nebolsin, Vladimir Evgenievich Induction method for cell differentiation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1206275A1 (en) * 1982-10-25 1986-01-23 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Disodium salt of 2-(2,6-dimethyl-3,5-diethoxycarbonyl-1,4-dihydropyridine-4-carboxamido) glutaric acid possessing antiarrhythmic activity
RU2141483C1 (en) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Peptide derivatives or their pharmaceutically acceptable salts, method of their synthesis, use and pharmaceutical composition
RU2335495C2 (en) 2005-06-15 2008-10-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" N-acyl derivatives of aminoacids, their pharmaceutically acceptable salts, pharmaceutical composition and application as hypolipidemic preparations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050180953A1 (en) * 2002-02-28 2005-08-18 Nebolsin, Vladimir Evgenievich Induction method for cell differentiation

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382179A (en) * 2013-06-05 2013-11-06 四川百利药业有限责任公司 Ingavirin polymorph and its preparation method
CN105307650A (en) * 2014-01-20 2016-02-03 瓦伦塔有限责任公司 Tablet-formed pharmaceutical composition and preparation method thereof
KR20160128416A (en) * 2014-03-12 2016-11-07 오브셰스트보 에스 오그라니첸노이 오트베트스트벤노스티주 “파름엔터프라지즈” Amide compounds and methods for the production and use thereof
JP2017511374A (en) * 2014-03-12 2017-04-20 オブシェストヴォ エス オグラニケノイ オトヴェツヴェノスチュ “ファーメンタープライゼズ” Amide compounds, methods for their preparation and use as medicaments for the treatment and prevention of diseases and complications caused by RNA and / or DNA-containing viruses.
EP3431469A1 (en) * 2014-03-12 2019-01-23 Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
KR102410255B1 (en) 2014-03-12 2022-06-20 오브셰스트보 에스 오그라니첸노이 오트베트스트벤노스티주 “파름엔터프라지즈” Amide compounds, methods for preparation, and use thereof as agents for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
IL247704B (en) * 2014-03-12 2022-07-01 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Amide compounds, methods for preparation, and use thereof as agents for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
US20170023593A1 (en) * 2014-04-03 2017-01-26 Koninklijke Philips N.V. High sensitive detection of melatonin
CN105435233A (en) * 2014-08-06 2016-03-30 江苏正大丰海制药有限公司 Ingavrin pharmaceutical composition
RU2665638C1 (en) * 2017-05-24 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Amide compound , and use as agents for treatment and prevention of diseases caused by rna-containing viruses
CN113861096A (en) * 2021-10-19 2021-12-31 中国农业大学 Compound containing indole structure, preparation method and application thereof

Also Published As

Publication number Publication date
US20130324540A1 (en) 2013-12-05
WO2009116896A1 (en) 2009-09-24
US8912185B2 (en) 2014-12-16
RU2373934C1 (en) 2009-11-27
UA104420C2 (en) 2014-02-10
EA201071098A1 (en) 2011-02-28
RU2008110644A (en) 2009-09-27
EA018127B1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
US8912185B2 (en) Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents
US20220202745A1 (en) Toxic aldehyde related diseases and treatment
EP2990402A1 (en) Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate
EP3838887B1 (en) 2-(1-acyloxypentyl) benzoic acid salt formed by basic amino acid or aminoguanidine, preparation method therefor and uses thereof
CN112638866A (en) Co-crystal of sorafenib derivative and preparation method thereof
EP3242869B1 (en) Compositions and methods for the treatment of inflammation and pain
US20200385351A1 (en) Compounds for modulating mitochondrial function
US8871805B2 (en) Compound, composition and uses thereof
JP2006507359A (en) Use of glycogen phosphorylase inhibitors for the treatment of cardiovascular disease
JPS63310820A (en) Phenol thioalkylamide compound as 5-lipoxygenase inhibitor
US20120270908A1 (en) Substituted 3 -hydrozypyridines and pharmaceutical compositions thereof
CN113387909B (en) Medical application of 2, 3-epoxysuccinyl derivative
KR20110015141A (en) Pharmaceutical composition comprising piperazine dithioctate and acetyl-l-carnitine
WO2023134732A1 (en) Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids
EP4186503A1 (en) Anti-inflammatory composition comprising benzofuran-based n-acylhydrazone derivatives
RU2617428C2 (en) 5-bromonicotinic acid derivatives with anti-arrhythmic activity
CN114349665A (en) Metformin pyroglutamic acid crystal and preparation method and application thereof
US20100179209A1 (en) Pactimibe medicaments for preventing/treating a disease due to sebaceous gland dysfunction in humans or animals

Legal Events

Date Code Title Description
AS Assignment

Owner name: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "PHARM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NEBOLSIN, VLADIMIR EVGENIEVICH;BLINOV, DMITRY SERGEEVICH;BALASHOV, VLADIMIR PAVLOVICH;AND OTHERS;REEL/FRAME:025528/0316

Effective date: 20101028

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION